Families fighting to get approval for a new drug that treats a fatal disease called Duchenne muscular dystrophy may glean some hope from the fact that federal drug regulators have bent to pressure from patient advocates in the past, according to Aaron Kesselheim, assistant professor of medicine at Brigham and Women’s Hospital.
